E H Bae1, S Y Lim2, K-D Han3, J-Hy Jung3, H S Choi1, C S Kim1, S K Ma1, S W Kim1. 1. 1 Department of Internal Medicine, Chonnam National University Medical School, Gwangju. 2. 2 Department of Internal Medicine, Korea University Ansan Hospital, Ansan, Korea. 3. 3 Department of Medical Statistics, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Abstract
OBJECTIVE: Specific differences in cancer risk have been observed between systemic lupus erythematosus patients and the general population. Although meta-analyses have estimated cancer incidence in systemic lupus erythematosus patients, results have been inconclusive. Hence, we aimed to assess malignancy risk in systemic lupus erythematosus patients, compared to the risk in the general population. METHODS: Systemic lupus erythematosus patients ( n = 21,016; mean age 41.67 ± 13.14 years; female 90.22%) were selected from the Korean National Health Insurance Service database between 2008 and 2014. Age- and sex-matched controls were randomly sampled in a 5:1 ratio ( n = 105,080). RESULTS: During the 7 years of follow up, malignancy was detected in 763 (3.63%) systemic lupus erythematosus patients and 2667 (2.54%) controls. Systemic lupus erythematosus patients had a higher risk of malignancy than controls (odds ratio 1.44; 95% confidence interval 1.327-1.559), after multivariate adjustment. Systemic lupus erythematosus patients had a higher odds ratio for developing cervical, thyroid, ovarian, and oral cancer, as well as lymphoma, leukemia, and multiple myeloma than controls. Based on subgroup analysis, male systemic lupus erythematosus patients and patients younger than 40 years showed the highest lymphoma risk. CONCLUSIONS: Systemic lupus erythematosus might be an independent risk factor for cancer. Therefore, the importance of cancer screening programs should be emphasized in systemic lupus erythematosus patients. Our study is the first large nationwide cohort study for evaluating the risk of cancer in systemic lupus erythematosus patients.
OBJECTIVE: Specific differences in cancer risk have been observed between systemic lupus erythematosuspatients and the general population. Although meta-analyses have estimated cancer incidence in systemic lupus erythematosuspatients, results have been inconclusive. Hence, we aimed to assess malignancy risk in systemic lupus erythematosuspatients, compared to the risk in the general population. METHODS:Systemic lupus erythematosuspatients ( n = 21,016; mean age 41.67 ± 13.14 years; female 90.22%) were selected from the Korean National Health Insurance Service database between 2008 and 2014. Age- and sex-matched controls were randomly sampled in a 5:1 ratio ( n = 105,080). RESULTS: During the 7 years of follow up, malignancy was detected in 763 (3.63%) systemic lupus erythematosuspatients and 2667 (2.54%) controls. Systemic lupus erythematosuspatients had a higher risk of malignancy than controls (odds ratio 1.44; 95% confidence interval 1.327-1.559), after multivariate adjustment. Systemic lupus erythematosuspatients had a higher odds ratio for developing cervical, thyroid, ovarian, and oral cancer, as well as lymphoma, leukemia, and multiple myeloma than controls. Based on subgroup analysis, male systemic lupus erythematosuspatients and patients younger than 40 years showed the highest lymphoma risk. CONCLUSIONS:Systemic lupus erythematosus might be an independent risk factor for cancer. Therefore, the importance of cancer screening programs should be emphasized in systemic lupus erythematosuspatients. Our study is the first large nationwide cohort study for evaluating the risk of cancer in systemic lupus erythematosuspatients.
Authors: Fruzsina Kósa; Péter Kunovszki; Judit Gimesi-Országh; Melinda Kedves; Melinda Szabó; Chetan S Karyekar; György Nagy Journal: Arthritis Res Ther Date: 2022-05-19 Impact factor: 5.606
Authors: Noémi Zádori; Lajos Szakó; Szilárd Váncsa; Nóra Vörhendi; Eduard Oštarijaš; Szabolcs Kiss; Levente Frim; Péter Hegyi; József Czimmer Journal: Front Immunol Date: 2021-11-23 Impact factor: 7.561